ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CHB Global X China Biotech Innovations ETF

6.64
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Name Symbol Market Type
Global X China Biotech Innovations ETF NASDAQ:CHB NASDAQ Exchange Traded Fund
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  0.00 0.00% 6.64 2.67 10.66 0 01:00:00

Rule 8 - Chubb plc

16/07/2003 12:09pm

UK Regulatory


RNS Number:6114N
Merrill Lynch Investment ManagersLd
16 July 2003


FORM 8.1/8.3

Lodge with Company Announcements Office (which will publicise and copy to the
Panel). Use separate form for each class of securities in which dealings have
been made.

     Date of disclosure: 16th July, 2003

DISCLOSURE UNDER RULES 8.1(a), 8.1(b)(i) AND 8.3 OF THE CITY CODE ON TAKE-OVERS
AND MERGERS

Date of dealing: 15th July, 2003

Dealing in:           Chubb plc          (Name of Company)

(1) Class of securities: 36p Ordinary Shares      (eg ordinary shares):

(2)

Amount bought                Amount sold                      Price per unit
                             685,474                          76p
                             2,172,116                        75.63p

(3)     Resultant total of the same class owned or controlled
       (and percentage of class 61,174,624     (7.37%)

(4)     Party making disclosure : MERRILL LYNCH INVESTMENT MANAGERS LIMITED


(5)     EITHER (a) Name of purchaser/vendor (note 1)

        OR     (b) If dealing for discretionary client(s), name of fund 
                   management organisation:

                   MERRILL LYNCH INVESTMENT MANAGERS LIMITED


(6)     Reason for disclosure (Note 2)

     (a) associate of (i) offeror (Note 3)     XXX/NO
                      (ii) offeree company     YES/XX

     Specify which category or categories of associate (1-8 overleaf)

             If category (8), explain  ..................Category 6.............

     (b) Rule 8.3 (ie disclosure because of ownership or control of 1% or more 
         of the class of relevant securities dealt in)     YES/XX

Signed, for and on behalf of the party named in (4) above

(Also print name of signatory): Katie Neate

Telephone and extension number 020 7964 5641


        Note 1.     Specify owner, not nominee or vehicle company. If relevant,
        also identify controller of owner, eg where an owner normally acts on
        instructions of a controller.

        Note 2.     Disclosure might be made for more than one reason: if so,
        state all reasons.

        Note 3.     Specify which offeror if there is more than one.

        Note 4.     When an arrangement exists with any offeror, with the
        offeree company or with an associate of any offeror or of the offeree
        company in relation to relevant securities, details of such arrangement
        must be disclosed, as required by Note 6 on Rule 8......................



                      This information is provided by RNS
            The company news service from the London Stock Exchange
END
DCCGUUMUMUPWGGQ

1 Year Global X China Biotech I... Chart

1 Year Global X China Biotech I... Chart

1 Month Global X China Biotech I... Chart

1 Month Global X China Biotech I... Chart

Your Recent History

Delayed Upgrade Clock